Giles, H., Lansdell, S.J., Bolofo, M.-L., Wilson, H.L. and Martin, G.R. (1996) Characterization of a 5-HT1B Receptor on CHO Cells: Functional Responses in the Absence of Radioligand Binding. British Journal of Pharmacology, 117, 1119-1126.
https://doi.org/10.1111/j.1476-5381.1996.tb16705.x

has been cited by the following article:

• TITLE: Differences in the Receptor Binding Profile of Lofexidine Compared to Clonidine

  AUTHORS: Robert B. Raffa, Joseph V. Pergolizzi, Robert Taylor, Robert P. James, Mark Pirner

  KEYWORDS: Lofexidine, Clonidine, Opioid Withdrawal, Receptor Affinity, Alpha-2 Agonist

  JOURNAL NAME: Pharmacology & Pharmacy, Vol.10 No.1, January 3, 2019

  ABSTRACT: Lucemyra? (lofexidine hydrochloride) has recently been approved by the US FDA for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. Lofexidine is an alpha-2 adrenoceptor agonist. However, the clinical attributes of lofexidine differ in advantageous ways from the classical alpha-2 adrenoceptor agonist clonidine. In the present study, we measured the receptor binding profile of lofexidine and clonidine in an effort to gain an insight into the clinical difference(s).